The World Market for Molecular Diagnostics Tests, 11th Edition

There is a market in excess of $21 billion for molecular testing technologies.  For comparison purposes, this is nearly the size of the IVD market two decades ago.  The majority of the market is COVID-19, but there remains a sizable market for other molecular IVD applications, from cancer to transplant typing to infectious diseases.  This Kalorama Information report assess the business opportunity in each of these areas.    Molecular diagnostics proved themselves during the COVID-19 pandemic, but the market in 2022 is a different place.  Kalorama Information's 11th Edition report of the clinical molecular testing industry provides marketing sizing and forecasts for IVDs over a five-year period.  

Overall Market

• Infectious Disease Molecular Diagnostics (COVID-19, Hepatitis, HIV, Respiratory, STI, HAIs, Others)
• Cancer Molecular Diagnostic Markets (Blood-based and Tissue-based)
• Genetic Molecular Diagnostic Markets (SNPs, Inherited, NIPT, Other)
• Blood Banking Molecular Diagnostics Markets
• Transplantation Molecular Diagnostic Markets
• Regional Molecular Diagnostics Markets (North America, Europe, Asia, Global)

This report is published as the industry experienced accelerated installed bases and new product introductions.  Molecular diagnostics has always been a fast-evolving and dynamic field.  Taken together, it is the fastest growing segment within the in vitro diagnostics (IVD) market. It has become an indispensable tool in clinical medicine that touches all aspects of healthcare including treatment decisions in terms of identifying antimicrobial resistant (AMR) infections at the earliest, companion diagnostics assisting in the evaluation of suitability of various cancer treatment options, pharmacokinetics or patient metabolism of drugs for HIV, psychiatric conditions or blood thinners; cancer prognosis and therapy, organ matching, blood safety, and the diagnosis of latent and neonatal conditions.

This market is heavily competitive.  Companies considered include:

• Roche
• Abbott
• Thermo Fisher
• Meridian Bioscience
• Myriad
• Perkin Elmer
• Cepheid
• BioMérieux
• Promega
• QuantuMDX
• QuidelOrtho
• Hologic
• Qiagen
• ARUP
• Asuragen
• CareDX
• Vela Diagnostics
• Becton, Dickinson &Co.
• BGI
• Bio-Rad
• Leica Biosystems
• Greiner Bio-One
• Biocartis
• Credo
• Eiken
• CTK
• Leica Biosystems  
• Grifols
• Illumina
• T2